 |
|
The Central Drug Regulatory Authority (CDRA) has issued a warning regarding the quality of pharmaceutical products in the market. A recent drug test revealed that 49 drug samples, including widely used medications such as Shelcal 500, Pan-D, and paracetamol, failed to meet quality standards. This discovery underscores the critical need for robust drug regulation and quality control mechanisms to protect public health.
The CDRA inspected approximately 3,000 drug samples, with 1.5% failing to meet the required standards. The list of substandard drugs includes a variety of medications, ranging from calcium supplements to antibiotics and anti-inflammatory drugs. Notably, popular brands like Alkem Health Science, Aristo Pharmaceuticals, and Hindustan Antibiotics were represented among the failing products.
Despite the findings, manufacturers of the implicated drugs have vehemently denied responsibility. They claim that the substandard batches were not produced by them and that the products are spurious. The CDRA is currently investigating these allegations and taking steps to ensure the safety of the drugs circulating in the market.
The CDRA's investigation and subsequent recall of substandard drugs highlight the potential risks associated with consuming ineffective or harmful medications. The World Health Organization (WHO) has cautioned that the use of such drugs can lead to serious health consequences, including therapeutic failure, exacerbation of disease, drug resistance, and even death. Substandard drugs can hinder the treatment of chronic and infectious diseases, leading to disease progression and increased mortality.
The CDRA's actions underscore the importance of stringent regulatory measures to ensure the quality and safety of pharmaceutical products. Consumers must be vigilant and exercise caution when purchasing and consuming medications. They should always verify the authenticity and quality of drugs through reputable sources and report any suspicions to the relevant authorities.
The CDRA's ongoing efforts to address the issue of substandard drugs are crucial for protecting public health. By proactively identifying and removing faulty products from the market, the authority can mitigate the risks associated with drug quality failures and contribute to a safer healthcare system.
Source: Shelcal 500, PAN-D, Paracetamol, 46 other drugs fail quality test. Do you consume? Check list here